Human ErbB3 / Her3 Protein, His Tag (MALS verified)
分子別名(Synonym)
ERBB3,HER3,LCCS2,MDA-BF-1,MGC88033,c-erbB3,erbB3-S,p180-ErbB3,p45-sErbB3,p85-sErbB3
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human ErbB3, His Tag (ER3-H5223) is expressed from human 293 cells (HEK293). It contains AA Ser 20 - Thr 643 (Accession # P21860-1).
Predicted N-terminus: Ser 20
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 70.5 kDa. The protein migrates as 70-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 0.1 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
ErbB3,也稱為Her3(人表皮生長(zhǎng)因子受體3),是受體酪氨酸激酶的表皮生長(zhǎng)因子-受體(EGFR)家族的成員。這種膜結(jié)合糖蛋白具有神經(jīng)調(diào)節(jié)蛋白結(jié)合結(jié)構(gòu)域,但沒(méi)有活性激酶結(jié)構(gòu)域。因此,它可以結(jié)合配體,但不能通過(guò)蛋白質(zhì)磷酸化介導(dǎo)細(xì)胞內(nèi)信號(hào)轉(zhuǎn)導(dǎo)。然而,它確實(shí)與ErbB2或其他負(fù)責(zé)酪氨酸磷酸化的EGFR成員形成異二聚體,以產(chǎn)生受體復(fù)合物并啟動(dòng)相關(guān)途徑,從而導(dǎo)致細(xì)胞增殖或分化。據(jù)報(bào)道,這種蛋白在許多癌癥中過(guò)表達(dá),包括前列腺、膀胱和乳腺腫瘤。該蛋白具有不同的異構(gòu)體,來(lái)源于選擇性剪接變體,其中,缺乏膜間區(qū)域的分泌型異構(gòu)體調(diào)節(jié)膜結(jié)合形式的活性。
關(guān)鍵字: ErbB3;ErbB3蛋白;ErbB3重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。